SiteOne Therapeutics

SiteOne Therapeutics, Inc. is a biopharmaceutical firm established in 2011, focusing on the development of non-opioid pain relief medications. The company was co-founded by George Miljanich and John Hunter, who both possess extensive experience in the field of neuroscience and ion channel modulation from their time at Elan Pharmaceuticals. Their work is rooted in over three decades of research into the biology and structure of the Nav1.7 sodium ion channel, a genetically validated target for pain signals.

The company's primary business involves discovering and advancing a new class of highly selective sodium ion channel (Nav) inhibitors. By targeting Nav1.7, SiteOne aims to stop the transmission of pain signals at their source without the central nervous system side effects and addictive potential associated with opioids. This positions the company within the specialty pharmaceutical market, specifically addressing the significant unmet need for safer and more effective analgesics for conditions like acute, chronic, and neuropathic pain. The business model is typical of a clinical-stage biopharmaceutical company, revolving around research and development, securing intellectual property, and progressing drug candidates through the FDA's clinical trial phases, with revenue generation likely tied to partnerships, licensing deals, or eventual commercialization of an approved drug.

SiteOne's lead product candidates are ST-2427 and ST-2645, which are being investigated for treating moderate-to-severe pain. ST-2427, an oral medication, has successfully completed Phase 1 clinical trials, demonstrating a favorable safety and tolerability profile. The development of these candidates is supported by a robust intellectual property portfolio. A significant milestone was achieved in 2024 when the company secured an oversubscribed $45 million Series D financing round, co-led by Braidwell LP and existing investor TPG's The Rise Fund. This funding is intended to advance ST-2427 through Phase 2 clinical trials for multiple pain indications.

Keywords: non-opioid analgesics, pain relief, Nav1.7 inhibitors, biopharmaceutical, sodium ion channel, neuropathic pain, clinical trials, drug development, life sciences, specialty pharma